Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update.

Hepatol Int · 2008 · PMC2716890 · PMID 19669255

Europe PMC DOI

hedged sentence

0.0670

closest p · 1.3× alpha

0.0670

boldest claim

The sentences

marginal significanceP = 0.067so close (0.05 < p ≤ 0.1)

A randomized controlled trial in 96 patients showed that lymphoblastoid IFN 5 MU in combination with thymosin α-1 1.6 mg 3 times weekly for 24 weeks increased HBeAg loss 1 year after the end of treatment with marginal significance in comparison with IFN monotherapy (45.8% vs. 28%; P = 0.067) [ 57 ].

also in 3,113 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.